Dr. Bhuvan Chugh is a distinguished Medical Oncologist and clinical leader known for empathetic, clear, and evidence-based cancer care. He specializes in Breast and Thoracic cancers, with a strong interest in using molecular oncology to personalize treatment and improve clinical decision-making.
He is recognized for practicing precision-led oncology, integrating genomic testing where it can meaningfully influence treatment strategy. His notable work includes CSF-based genomic sequencing-guided management in EGFR-mutant lung cancer with leptomeningeal disease, presented at ALKlinic 2025 and published in the Journal of Liquid Biopsy. He has also served as Past Convenor of the Max Healthcare–Foundation Medicine India Molecular Tumor Board, contributing to complex multidisciplinary decision-making across disease-site tumor boards.
Dr. Chugh previously served as Principal Consultant, Medical Oncology at Max Super Specialty Hospital (Saket and Gurugram) and as Clinical Lead, Medical Oncology at Max Hospital, Gurugram, where he helped build and scale medical oncology services into a comprehensive, process-driven program with strong multidisciplinary integration.
Earlier, he worked at Medanta, The Medicity (Gurugram) in the Department of Medical Oncology & Hematology after completing his DNB in Medical Oncology, gaining broad experience in managing complex cancers in a tertiary-care setting.
He has presented his work at ASCO and ESMO through multiple abstracts and posters, and is currently Lead Consultant, Medical Oncology at Apollo Hospitals (Delhi–NCR network). His practice is firmly defined by patient-first care, evidence-based protocols, molecular oncology, and practical clinical judgment. He is also known for helping patients navigate difficult medical choices with clarity and confidence, an approach he has also shared as a TEDx speaker.
Special interest
- Breast, Thoracic, Head & Neck cancers, Sarcomas
- Precision Oncology Leader: CSF genomic sequencing–guided treatment in lung cancer (landmark publication).
- Treatment of complex breast cancer cases, including post initial lines of therapy, those with with leptomeningeal disease and those with co-morbidities
- Built and led a comprehensive oncology program at Max Gurugram
- Academics: ASCO/ESMO presentations + indexed publications.
- Advacned Certification in Molecular Oncology (Sidney Kimmel/Thomas Jefferson)
Memberships
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- Internation Association for the Study of Lung Cancer (IASLC)
- Indian Society of Medical & Pediatric Oncology (ISMPO)
- Indian Medical Association (IMA) Oncology Forum
Awards & Achievements
- Clinical advisor to genomics and precision diagnostics initiatives in India
- Multiple ASCO/ESMO presentations and indexed publications (first author & co-author)
- TEDx Speaker
- IMA (NDB) Award of Excellence in Oncology (2024)
- BusinessWorld (BW) 40 Under 40 Award recipient
- Member ISMPO–Illumina Precision Oncology Working Group (2024)
- Presented CSF genomic sequencing–guided management of leptomeningeal disease in EGFR-mutant NSCLC (ALKlinic 2025, Taipei, Taiwan)
- Invited Speaker: SCCHN Preceptorship, Centre Antoine Lacassagne, Nice, France (Nov 2025)
- ESMO Asia 2024 – Best Poster Award (co-author)
- Contributor to breast & lung cancer consensus and guideline-driven practice
- Former Convenor, Max Healthcare–Foundation Medicine Molecular Tumor Board
Certifications
- Advanced Certification in Molecular Oncology (Sidney Kimmel/Thomas Jefferson)
Research & Publications
- Presentations in International conferences
- OncoTwin Insights: A Clinicogenomic Similarity-Based Decision Support System for Precision Therapy in Lung Cancer. (ID 2248). Poster Presentation – ESMO Asia, December 2025, First Author.
- Comprehensive germline sequencing and MLPA analysis in breast cancer patients: 4 years of experience from an Indian cancer institute. (First Author, Accepted as Online Only presentation in ASCO Annual Meeting 2025)
- Driving precision oncology in lung cancer: Patient stratification through comprehensive genomic profiling. (Co-Author, Accepted as Poster in ASCO Annual Meeting 2025)
- Landscape of Metastatic Colorectal Cancer (CRC) using Comprehensive circulating tumor DNA (ctDNA) Next Generation Sequencing (NGS) in India: Expanding Beyond RAS and RAF. (Co-Author, Accepted Poster in ASCO GI 2025)
- Genomic mutational profile of breast cancer patients from India through comprehensive next-generation sequencing analysis of circulating tumor DNA. ESMO 2024 – Best Poster Award
- Circulating tumor cells in clinically stable patients demonstrates the conundrum of recurrence with cellular residual disease. ASCO Annual Meeting 2024
- Differences in the Clinicopathological Feature, Prognostic Features and Treatment Outcomes between Molecular Subtypes Among Indian Cohort with Diffuse Large B- Cell Lymphoma - a Single Centre Experience; Blood 134 (Supplement_1):5350-5350.; November 2019
- A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre; Blood 134 (Supplement_1):5559-5559; November 2019
- Abstract Publication in BTG2018, 9th International Hematologic Malignancies Conference held in Seoul, South Korea from March 29-31, 2018
- In National Conferences:
- A Prospective Study of Clinico-pathological features, Prognostic factors, and Response rates in Advanced Non-small Cell Lung Cancer Patients Eligible for Chemotherapy - A Single Centre Experience at 37th ICON New Delhi. 2017
Publications:
Chapters in a book:
- Systemic Therapies in Hepatocellular Carcinoma (In Publication)
- Chapter titled ‘Key Takeaways from International Guidelines on Gastric Cancer’ in the book ‘Gastric Cancer’ by Springer Healthcare Education
- Chapter titled ‘Biomarkers in Cardiac Disease’ in the book ‘Progress in Medicine’ Volume XXIX year 2015 by Association of Physicians of India-Indian College of Physicians (API-ICP)
Publications:
- Malik PS, Baral R, Chugh B, Dawoud E, Forde P, Ghosn M, et al. Excellence in oncology care (EIOC) consensus guidelines on integrating immunotherapy (IO) in resectable non-small cell lung cancer (NSCLC) for the Middle East and Indian subcontinent. Cancer Res Stat Treat. 2025 Oct-Dec;8(4):298-303. doi:10.4103/crst.crst_15_25.
- Chugh B, et al. Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC. J Liq Biopsy. 2025;10:100332.
- Investigating the genomic landscape of sarcoma in India: Discoveries from a retrospective observational approach in Cancer Research, Statistics and Treatment, August 2025 (contributing author)
- Rastogi, R. et al. (2024) ‘Von Meyerberg complexes: An underrecognized predisposing factor for focal nodular hyperplasia–like lesions’, Indian Journal of Radiology and Imaging [Preprint]. doi:10.1055/s-0044-1801266.
- Molecular insights from comprehensive genomic profiling data in advanced metastatic colorectal cancer in South Asian population: A retrospective observational study; Cancer Research, Statistics and Treatment 7(2):p 193-205, Apr–Jun 2024
- Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukaemia; Annals of Hematology 98(3); March 2019
- Myelodysplastic syndromes: Where do we stand? Asian Journal of Oncology. April 2016
- Outcomes of patients presenting with acute coronary syndrome with vitamin D deficiency. Indian Heart Journal. November 2014
- DOTS expansion under the umbrella of IMA: Success story continues along with early teething difficulties. Journal of the Indian Medical Association. July 2008
Research Work
- Evaluation of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTC) for detecting Minimal Residual Disease in Early-Stage Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy. REACT Study
- A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as First-line Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS greater than/equal to 50% at Max Super Speciality Hospital (Site Verification Ongoing)
- A Registry To Collect Characteristics And Outcomes From Patients With Solid Tumors Profiled With A Next-Generation Sequencing Test (WAYFIND-R).
- A Prospective, Multicenter, Non-Interventional, Observational, Real-World Study to Evaluate the Safety, Adherence to Therapy, and Effectiveness of a T-DM1 Antibody Drug Conjugate Biosimilar in Indian Patients with HER2-Positive Early Breast Cancer
Ask your query
Have a question? Ask your query below.
Best Hospital Near me Chennai